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Objective: To assess the cross‐sectional and prospective associations between
depressive symptoms, neuroticism, and participation in breast and cervical screening
in the UK.
Methods: Women in the UK Biobank cohort with complete data who were eligible
for breast cancer screening (aged 50‐70 years, N = 143 461) and/or cervical screen-
ing (<65 years, N = 141 753) at baseline recruitment (2006‐2010) and those with
follow‐up data (2014‐2019) were identified (N = 11 050 and N = 9780 for breast
and cervical screening). Depressive symptoms and neuroticism were self‐reported
at baseline (range 0‐12 with higher scores reflecting greater severity). Primary out-
comes were reporting being up to date with breast and cervical screening. For pro-
spective analyses, patterns of screening participation from baseline to follow‐up
were identified. Logistic regression was used to analyse associations, adjusted for
potential confounding factors.
Results: More severe depressive symptoms were associated with reduced likeli-
hood of breast (OR = 0.960, 95% CI: 0.950,0.970) and cervical (OR = 0.958, 95%
CI: 0.950,0.966) screening participation, in cross‐sectional analyses. Higher neuroti-
cism scores were associated with reduced cervical screening participation, but the
opposite was found for breast cancer screening. Examination of individual neuroti-
cism items revealed that anxiety and worry were associated with increased breast
screening. At follow‐up, higher baseline depressive symptoms were related to
decreased cervical screening (OR = 0.955, 95% CI: 0.913,0.999), but not with breast
screening.
Conclusions: More severe depressive symptoms may be a barrier for breast and
cervical screening and could be an indicator for more proactive strategies to improve
uptake.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Globally, more than two million women are diagnosed with breast or
cervical cancer every year.1 The UK has one of the highest incidence
rates of breast cancer, a leading cause of death amongst women. Cer-
vical cancer is the 14th most common cancer amongst women in the
UK, although incidence has fallen over the past few decades due to
effective population‐based screening programmes.2 The National
Health Service (NHS) Cervical Screening Programme was introduced
in the UK in 1988. All women who are registered with a GP are invited
to attend for screening every 3 years if aged 25 to 49, every 5 years if
aged 50 to 64, and only women who have recently had abnormal tests
are invited if aged 65 and over. Also introduced in 1988, the NHS
Breast Screening Programme currently invites all women aged
between 50 and 70 for screening every 3 years.3
A number of social and psychological factors influence participa-
tion in breast and cervical screening. Several studies have demon-
strated social inequalities in screening participation by education
level,4 area‐level deprivation,5 and ethnicity.6 Individuals with psychi-
atric disorders are less likely to attend breast and cervical screening,7,8
particularly those with severe mental illness.9 The presence of a high
depressive symptom burden has also been associated with nonatten-
dance at breast screening,10-12 but not cervical screening.10,11
Few studies have examined the role of personality factors in can-
cer screening attendance.13-17 Those that have are limited by small
samples and cross‐sectional designs. One important aspect of person-
ality that could be hypothesised to impact on screening behaviour is
neuroticism. Neuroticism refers to the relatively stable propensity to
respond with negative emotions to threat, frustration, or loss.18
Neuroticism has an underlying neurobiological basis,19 is strongly cor-
related with depressive and anxiety disorders,20 and is associated with
significant economic costs to society via mental health service usage
and productivity losses.21 Aspects of neuroticism, such as mood insta-
bility, may decrease the likelihood of attending screening, whereas
anxiety may increase screening attendance if individuals are worried
about their risk of cancer.22 Whether neuroticism predicts screening
participation independently of depressive symptoms, and whether
specific aspects of neuroticism or symptoms of depression are more
strongly related to screening behaviour remains to be elucidated.
Greater awareness of aspects of neuroticism which affect uptake
could inform public health messaging about screening programmes,
as well as how health professionals communicate with individuals
who may require additional support to access screening or reduce
anxiety associated with it.23
The aim of this study was to investigate both cross‐sectional and
prospective associations between depressive symptoms, neuroticism,
and participation in breast and cervical screening amongst women inthe UK Biobank cohort. We had four key objectives: (a) to investigate
the cross‐sectional associations between depressive symptoms (over-
all and item‐specific questions) and participation in breast and cervical
screening; (b) to examine the cross‐sectional associations between
neuroticism (overall score and item‐specific questions) and participa-
tion in breast and cervical screening; (c) to examine whether baseline
depressive symptoms and neuroticism scores predict future participa-
tion in breast and cervical screening; and (d) to investigate whether
baseline depressive symptoms and neuroticism scores relate to longi-
tudinal patterns of breast and cervical screening participation.2 | METHODS
2.1 | Data
We used secondary data from UK Biobank (further details are found at
https://www.ukbiobank.ac.uk/), which achieved a 5.5% response
rate.24 Over 502 000 community‐dwelling individuals aged 37 to 73
years were recruited to UK Biobank during 2006 to 2010, forming
the baseline sample.25 They attended one of 22 assessment centres
distributed across England, Scotland, and Wales where data were col-
lected on a range of topics including lifestyle, socio‐demographics,
physical, and mental health. UK Biobank received ethical approval
from the NHS National Research Ethics Service North West (11/
NW/0382). This research has been conducted using the UK Biobank
resource under Application Number 41686. All participants gave writ-
ten informed consent.
We restricted the sample (Figure S1) to women aged 50 to 70
years at baseline for the breast screening analysis (N = 208 726) and
women aged under 65 years at baseline for the cervical screening
analysis (N = 224 805). Participants who reported that they had
undergone a hysterectomy at baseline were excluded from the cervi-
cal screening analysis (N = 12 804), as they are no longer eligible for
screening recall.
A repeat assessment of around 20 000 participants was carried out
between August 2012 and June 2013 at the UK Biobank Co‐
ordinating Centre in Cheadle, Stockport (further details in the Online
Supplementary Material). A further 36 000 individuals have taken part
in the UK Biobank Imaging Study at the Cheadle, Newcastle and Read-
ing assessment centres between May 2014 and March 2019 where
repeat assessment data were also collected (see https://imaging.
ukbiobank.ac.uk/). We identified 13 668 and 15 107 women from
the breast and cervical screening baseline samples who attended a
follow‐up assessment visit. Excluding participants who were no longer
eligible for screening at follow‐up on the basis of age, a total of 11 458
NIEDZWIEDZ ET AL. 3women were included in the breast screening prospective sample and
10 578 in the cervical screening prospective sample.2.2 | Outcomes
At baseline and follow‐up, participants were asked whether they had
ever been for breast cancer screening (a mammogram) and whether
they had ever had a cervical smear test. Those who answered “yes”
were asked how many years ago their last mammogram or cervical
smear test occurred. We combined these items to form baseline and
follow‐up variables distinguishing those who were up to date with
their breast screening (≤3 years since last screened) versus those
who were not (never been for screening or >3 years since last
screened). For cervical screening, “up to date with screening” was
defined as those who had a cervical smear test ≤3 years ago for par-
ticipants aged under 50 years and ≤5 years ago if aged 50 years and
over. For the prospective analyses, we also grouped individuals into
longitudinal patterns of engagement with breast and cervical screen-
ing including up to date with screening at baseline and follow‐up; up
to date at baseline only; up to date at follow‐up only; or up to date
at neither time point.2.3 | Exposure variables
Recent depressive symptoms were measured at baseline via
four questions adapted from the Patient Heath Questionnaire‐9
(PHQ‐9)26 which were included in UK Biobank, (eg, “Over the past
two weeks, how often have you felt down, depressed or hopeless?”).
Participants selected either “not at all” (scored 0), “several days”
(scored 1), “more than half of the days” (scored 2), or “nearly every
day” (scored 3). Answers were summed to produce a scale ranging
from 0 to 12, with higher scores reflecting more severe current
depressive symptoms (further details in the Supporting Information).
The individual items were categorised into “nearly every day”
(representing probable depression) versus all others.
Neuroticism was measured at baseline via 12 questions from the
brief Eysenck Personality Inventory Neuroticism Scale (EPIN‐R)27,28
which were included in UK Biobank, (eg, “Does your mood often go
up and down?”). Participants answered either “no” or “yes.” Answers
were summed to produce a neuroticism score ranging from 0 to 12,
where 12 represents high neuroticism.2.4 | Potential confounders
We included several potential baseline confounding variables: age
group; ethnicity (White, Black, South Asian, Chinese, Mixed/Other);
region (Scotland, England or Wales); education level; area‐level socio-
economic deprivation assessed using Townsend score29; self‐reported
long‐standing illness or disability. Lifestyle factors including smoking
(never, previous, current), body mass index (BMI), and alcohol con-
sumption (daily or almost daily, 3‐4 times a week, once or twice a
week, 1‐3 times per month, special occasions, or never) were includedas potential confounding or mediating variables. Full details are pro-
vided in the Supporting Information.2.5 | Statistical analysis
We first descriptively examined mean neuroticism and depressive
symptom scores for women who were up to date with their screening
compared with those who were not. For the cross‐sectional analyses,
a series of logistic regression models were calculated predicting
whether participants were up to date with their breast and cervical
screening (further details in the Supporting Information). We calcu-
lated logistic regression models for the two screening outcome vari-
ables including neuroticism scores, adjusted for education level,
socioeconomic deprivation, ethnicity, region, and long‐standing illness
or disability, followed by lifestyle factors (smoking, alcohol consump-
tion, and BMI).
We then calculated models including the 12 individual neuroticism
items (instead of the neuroticism scores as we hypothesised that there
may be differences in the strength and/or direction of the associations
between the different questions), adjusted for the potential confound-
ing variables, followed by the addition of lifestyle factors.
We then tested the summed depressive symptom scores and then
the four individual depressive symptom items (both adjusted for neu-
roticism scores). Depressive symptoms were added after adding the
neuroticism items as we hypothesised that any potential causal path-
way would go from neuroticism to depressive symptoms as neuroti-
cism is a more stable trait. Predicted probabilities were calculated
and graphed to help interpret the results.
We then calculated logistic regression models predicting whether
participants were up to date with breast and cervical screening at
follow‐up, adjusted for baseline neuroticism scores and depressive
symptoms, baseline confounding variables and time between baseline
and follow‐up. We then added the equivalent baseline screening vari-
able, followed by baseline lifestyle factors.
Multinomial logistic regression models were then calculated using
the longitudinal screening pattern groups as the outcome variables
(with the reference group being up to date at both time points), includ-
ing baseline neuroticism and depressive symptom scores, adjusted for
baseline confounders and time between baseline and follow‐up. We
then added the baseline lifestyle variables. All statistical models in
the prospective analyses adjusted for the number of years between
the baseline and follow‐up data collection (as a series of dummy vari-
ables to allow for nonlinear relationships).
We conducted complete case analyses, excluding participants with
missing data for any variable. In the cross‐sectional analyses, 65 265
women in the breast cancer screening analyses and 70 248 in the cer-
vical screening analyses had missing data and were excluded. In the
prospective analyses, an additional 408 and 798 women had missing
outcome data and were excluded from the breast and cervical screen-
ing analyses, respectively. Several sensitivity analyses were performed
to test the robustness of the results (full details are available in the
Supporting Information). Multicollinearity was checked by calculating
the variance inflation factor, and potential nonlinearity was assessed
TABLE 1 Descriptive statistics for the cross‐sectional samples






N % N %
Total 143 461 141 753
Age group
<45 years ‐ ‐ 19 391 13.7
45‐49 years ‐ ‐ 25 431 17.9
50‐54 years 30 942 21.6 28 753 20.3
55‐59 years 35 614 24.8 30 991 21.9
60‐64 years 45 485 31.7 37 187 26.2
65+ years 31 420 21.9 ‐ ‐
Ethnicity
White 138 932 96.8 135 326 95.5
Mixed or Other 1480 1.0 2121 1.5
South Asian 1275 0.9 1744 1.2
Black 1453 1.0 2115 1.5
Chinese 321 0.2 447 0.3
Region3 | RESULTS
3.1 | Sample description
In the cross‐sectional analyses, a total of 143 461 women were
included in the breast cancer screening sample and 141 753 in the cer-
vical screening sample (Table 1 and Table S1). Mean depressive symp-
tom and neuroticism scores were slightly higher amongst those who
were not up to date with their breast and cervical screening, compared
with those who were (descriptive statistics for the individual items are
found in Table S2). In the prospective analyses, a total of 11 050
women were included in the breast screening sample and 9780 in
the cervical screening sample. The average number of years between
baseline and follow‐up assessments was 6.3 years and 6.5 years (with
a minimum of two and maximum of 12 years) for the breast and cer-
vical screening samples, respectively. Most participants were up to
date with their screening at both baseline and follow‐up (86.3% for
breast screening and 83.7% for cervical screening) (Table S3).
Scotland 10 690 7.5 11 034 7.8
England 126 726 88.3 124 438 87.8
Wales 6045 4.2 6281 4.4
Education level
College or university degree 43 504 30.3 51 415 36.3
A levels or equivalent 16 345 11.4 18 886 13.3
GCSEs or equivalent 33 917 23.6 33 641 23.7
CSEs or equivalent 5933 4.1 8361 5.9
NVQ or equivalent 6517 4.5 6120 4.3
Other professional
qualifications
9776 6.8 7386 5.2
None of the above 27 469 19.1 15 944 11.2
Long‐standing illness
No 98 686 68.8 104 122 73.5
Yes 44 775 31.2 37 631 26.5
Smoking
Never 83 432 58.2 85 109 60.0
Previous 48 908 34.1 43 654 30.8
Current 11 121 7.8 12 990 9.2
Alcohol consumption
Daily or almost daily 25 789 18.0 23 486 16.6
Three or four times a week 30 089 21.0 31 815 22.4
Once or twice a week 36 137 25.2 38 025 26.8
One to three times a month 17 558 12.2 18 768 13.2
Special occasions only 20 698 14.4 18 628 13.1
Never 13 190 9.2 11 031 7.83.2 | Cross‐sectional results
Higher neuroticism scores were associated with decreased likelihood
of being up to date with cervical screening (OR = 0.978, 95% CI:
0.973,0.982) in cross‐sectional analyses (Table 2 and Table S4). This
association persisted and was strengthened by the addition of depres-
sive symptoms and lifestyle factors (smoking, alcohol consumption,
and BMI). Results were less clear for breast screening. Neuroticism
scores were related to increased likelihood of being up to date (OR
= 1.009, 95% CI: 1.002,1.016), only after adjustment for depressive
symptoms and lifestyle factors. Higher depressive symptoms were
associated with decreased likelihood of being up to date with both
breast (OR = 0.960, 95% CI: 0.950,0.970) and cervical screening (OR
= 0.958, 95% CI: 0.950,0.966). Both associations were attenuated
with the addition of lifestyle factors. The difference in the predicted
probability of being up to date with screening between those with
the highest and lowest depressive symptom scores was 0.034 for
breast and 0.043 for cervical screening (Figure 1).
Most depressive symptoms were related to reduced participation
in both breast and cervical screening (Figure 2), apart from depressed
mood for breast screening and restlessness for cervical screening.
Feeling tired and lethargic was related to reduced participation in both
breast and cervical screening.
Examination of the individual neuroticism items revealed some
interesting findings (Figure 2). Being “tense or highly strung” was most
strongly associated with reduced breast screening participation,
whereas being “anxious or a worrier” was related to increased partici-
pation. Reporting being a nervous person was associated with being
up to date with cervical screening, and loneliness was related to
reduced participation in both breast and cervical screening.
TABLE 2 Results from logistic regression models investigating the association between neuroticism, depressive symptoms, and breast (N = 143
461) and cervical (N = 141 753) cancer screening at baseline in UK Biobank
Breast Cancer Screening Cervical Screening
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3





















CI, confidence interval; N, number of individuals. *P < .05. **P < .01. ***P < .001.
Model 1: Neuroticism score, age group, ethnicity, education level, region, long‐standing illness, and socioeconomic deprivation.
Model 2: Model 1 + depressive symptoms.
Model 3: Model 2 + smoking + alcohol consumption + BMI.
FIGURE 1 Predicted probability of
screening according to depressive symptom
scores
NIEDZWIEDZ ET AL. 53.3 | Prospective results
Baseline depressive symptoms were not associated with breast
screening at follow‐up (Table S5). A modest association was found
between higher baseline depressive symptoms and reduced cervical
screening at follow‐up, which persisted when adjusting for baseline
cervical screening (OR = 0.955, 95% CI: 0.913,0.999). However, this
was attenuated when adjusting for baseline lifestyle factors. Baseline
neuroticism scores were not associated with breast or cervical screen-
ing at follow‐up. We found little evidence of associations between
baseline depressive symptoms and the subsequent pattern of breast
cancer screening (Tables S6 and S7).4 | DISCUSSION
In this large study of UK Biobank participants, we found that more
severe depressive symptoms were related to reduced likelihood ofbeing up to date with both breast and cervical screening. However,
differences between those with no depressive symptoms and those
with more severe symptoms were not large. Feeling tired and lethargic
almost every day in the last 2 weeks was related to decreased likeli-
hood of being up to date with both breast and cervical screening.
The pattern of results was less clear for neuroticism. Overall,
higher neuroticism scores were related to reduced cervical screening
participation and increased breast screening participation within
cross‐sectional analyses. Examination of individual items revealed that
those related to anxiety and worry tended to be associated with
increased breast screening, which may be driving the overall positive
association. Feeling lonely was associated with reduced likelihood of
being up to date with both breast and cervical screening.
Prospective analyses revealed little or no association between
baseline depressive symptoms and breast cancer screening. For cervi-
cal screening, more severe depressive symptoms were associated with
reduced likelihood of being up to date at follow‐up, but this was atten-
uated by lifestyle factors.
FIGURE 2 Results from cross‐sectional logistic regression models.
Footnote: A. Breast screening according to depressive symptoms. B. Cervical screening according to depressive symptoms. C. Breast screening
according to neuroticism items. D. Cervical screening according to neuroticism items.
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that psychiatric morbidity, poor self‐reported mental health, and a
higher depressive symptom burden are associated with nonparticipa-
tion in breast cancer screening.10-12,30,31 Although Vigod et al (2011)
found no association between the severity of depressive symptoms
and cervical screening participation in their overall sample of women
aged 18 to 67 years, subgroup analyses of participants aged 40 to 67
years revealed that those with a higher depressive symptom burden
were less likely to have had cervical screening in the previous 3 years.
The differing pattern of associations for specific depressive symptoms
between breast and cervical screening samples requires further explo-
ration and may be partly due to different characteristics of the samples.
Very few studies have assessed the relationship between personal-
ity and cancer screening behaviour, despite numerous studies investi-
gating how personality may influence risk of cancer32-34 (a link that
remains highly controversial).35 Type A personality traits (ie, sense of
time urgency, high job involvement, and competitiveness), but not
hostility, were predictive of mammography use amongst a sample of
postmenopausal women participating in the GAZEL Cohort Study of
employees of a French national gas and electricity company.17 Neu-
roticism was also inversely associated with past, present, and future
attendance at prostate cancer screening in a small sample of men in
Estonia,36 but not with bowel cancer screening, in a study of individ-
uals aged 60 to 75 years participating in the English Longitudinal
Study of Ageing.15 Our study highlights the importance of examining
individual neuroticism items. Items related to anxiety and worry werepositively related to breast screening, and these items were likely driv-
ing the overall positive association with neuroticism scores, but they
appeared less important for cervical screening. This could be because
breast cancer is much more common than cervical cancer and breast
cancer is also more common amongst women aged 65 to 69 years,
an age group covered by UK Biobank, whereas younger people are
more at risk of cervical cancer. Individuals may be more worried about
getting breast cancer compared to cervical cancer, which may lead to
increased screening uptake amongst individuals who have more anx-
ious personalities.
Key strengths of our study include the large sample size provided
by UK Biobank, the inclusion of both cross‐sectional and prospective
analyses, and the examination of both breast and cervical screening
outcomes. To our knowledge, no other study has examined the poten-
tial influence of individual neuroticism items and specific depressive
symptoms, or longitudinal patterns of cancer screening behaviour.4.1 | Study limitations
A number of limitations are acknowledged. Although large and with a
spread of individuals from different social and educational back-
grounds, UK Biobank is not fully representative of the general UK
population and demonstrates a “healthy volunteer” effect.37 Partici-
pants were also more likely to be older and live in socioeconomically
advantaged areas than nonparticipants.37 It is also possible that
NIEDZWIEDZ ET AL. 7individuals with more severe depressive symptoms may have been
less likely to volunteer for UK Biobank, but we believe the magnitude
of associations found in this study are likely to be underestimated due
to any selection bias.38 The prospective analyses also included a rela-
tively small number of the assessment centres. The screening outcome
data were self‐reported, which we were unable to validate, and may
therefore suffer from recall bias. It is possible that recall bias may be
stronger amongst people with more severe depressive symptoms
and higher neuroticism, with under‐ascertainment of cancer screening
more likely to bias the estimate towards the null. Depressive symp-
toms and neuroticism were also limited by the self‐reported data col-
lection, which may be affected by stigma.
4.2 | Clinical implications
Cancer screening should be accessible to all in society. Ensuring that
women with poor mental health are able to participate in breast and
cervical screening may help to prevent future cancer morbidity. For
example, if cost‐effective, women presenting to their General Practi-
tioner with poor mental health could be reminded and offered a
screening appointment if required and any anxieties could be
discussed. Research could also address the acceptability of self sam-
pling39 for women with psychiatric morbidity and the potential to
reduce mental health inequalities in screening participation. Adequate
prevention and treatment of depression could also help to improve
uptake of breast and cervical screening, which may contribute to the
reduction of health disparities and the prevention of multimorbidity.5 | CONCLUSIONS
Depressive symptoms may influence participation in cancer screening
programmes. Results for neuroticism were less clear. Future research
may benefit from the use of administrative cancer screening data
and incorporation of objective measures of depression, such as receipt
of an antidepressant prescription.
ACKNOWLEDGEMENTS
C.L.N. is supported by the Medical Research Council (grant number
MR/R024774/1). D.J.S. acknowledges support from a Lister Institute
Prize Fellowship (173096) and from the Medical Research Council
Mental Health Data Pathfinder Award (MC_PC_17217). S.V.K. is
funded by a National Health Service (NHS) Research Scotland Senior
Clinical Fellowship (SCAF/15/02), the Medical Research Council
(MC_UU_12017/13 & MC_UU_12017/15), and Chief Scientist Office
(SPHSU13 and SPHSU15). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of
the manuscript. This research has been conducted using the UK
Biobank resource under Application Number 41686. UK Biobank
was established by the Wellcome Trust medical charity, Medical
Research Council, Department of Health, Scottish Government and
Northwest Regional Development Agency. UK Biobank has also had
funding from the Welsh Government, British Heart Foundation, and
Diabetes UK.CONFLICT OF INTEREST
J.P.P. is a member of the UK Biobank Steering Committee. The authors
declare no other conflict of interest.
DATA AVAILABILITY STATEMENT
UK Biobank is an open access resource. Data are available to bona fide
scientists, undertaking health‐related research that is in the public
good. Access procedures are described at http://www.ukbiobank.ac.
uk/using‐the‐resource/.
ORCID
Claire L. Niedzwiedz https://orcid.org/0000-0001-6133-4168
Kathryn A. Robb https://orcid.org/0000-0002-1672-0411
REFERENCES
1. Ginsburg O, Bray F, Coleman MP, et al. The global burden of women's
cancers: a grand challenge in global health. The Lancet. 2017;389
(10071):847‐860.
2. Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening
on cervical cancer mortality: estimation using stage‐specific results
from a nested case–control study. Br J Cancer. 2016;115:1140.
3. Advisory Committee on Breast Cancer Screening. Screening for breast
cancer in England: past and future. J Med Screen. 2006;13(2):59‐61.
4. Damiani G, Basso D, Acampora A, et al. The impact of level of educa-
tion on adherence to breast and cervical cancer screening: evidence
from a systematic review and meta‐analysis. Prev Med. 2015;81:
281‐289.
5. Douglas E, Waller J, Duffy SW, Wardle J. Socioeconomic inequalities in
breast and cervical screening coverage in England: are we closing the
gap? J Med Screen. 2016;23(2):98‐103.
6. Lu M, Moritz S, Lorenzetti D, Sykes L, Straus S, Quan H. A systematic
review of interventions to increase breast and cervical cancer screen-
ing uptake among Asian women. BMC Public Health. 2012;12(1):413.
7. Mitchell AJ, Pereira IES, Yadegarfar M, Pepereke S, Mugadza V, Stubbs
B. Breast cancer screening in women with mental illness: comparative
meta‐analysis of mammography uptake. Br J Psychiatry. 2014;205(6):
428‐435.
8. Tuesley KM, Jordan SJ, Siskind DJ, Kendall BJ, Kisely S. Colorectal, cer-
vical and prostate cancer screening in Australians with severe mental
illness: retrospective nation‐wide cohort study. The Aust New Zealand
J Psychiatry. 2018;4867418814945.
9. Woodhead C, Cunningham R, Ashworth M, Barley E, Stewart RJ,
Henderson MJ. Cervical and breast cancer screening uptake among
women with serious mental illness: a data linkage study. BMC Cancer.
2016;16.
10. Pirraglia PA, Sanyal P, Singer DE, Ferris TG. Depressive symptom
burden as a barrier to screening for breast and cervical cancers.
J Womens Health. 2004;13(6):731‐738.
11. Vigod SN, Kurdyak PA, Stewart DE, Gnam WH, Goering PN. Depres-
sive symptoms as a determinant of breast and cervical cancer
screening in women: a population‐based study in Ontario, Canada.
Arch Women's Mental Health. 2011;14(2):159‐168.
12. Burton MV, Warren R, Price D, Earl H. Psychological predictors of
attendance at annual breast screening examinations. Br J Cancer.
1998;77:2014.
13. Siegler IC, Costa PT Jr. Personality and breast cancer screening behav-
iors. Ann Behav Med. 1994;16(4):347‐351.
8 NIEDZWIEDZ ET AL.14. Arai S, Nakaya N, Kakizaki M, et al. Personality and gastric cancer
screening attendance: a cross‐sectional analysis from the Miyagi
Cohort Study. J Epidemiol. 2009;19(1):34‐40.
15. Gale CR, Deary IJ, Wardle J, Zaninotto P, Batty GD. Cognitive ability
and personality as predictors of participation in a national colorectal
cancer screening programme: the English Longitudinal Study of Ageing.
J Epidemiol Community Health. 2015;69(6):530‐535.
16. Hill EM, Gick ML. The big five and cervical screening barriers: evidence
for the influence of conscientiousness, extraversion and openness.
Personal Individ Differ. 2011;50(5):662‐667.
17. Lemogne C, Turinici M, Panjo H, et al. Personality and breast cancer
screening in women of the GAZEL cohort study. Cancer Med.
2017;7(2):515‐524.
18. Lahey BB. Public health significance of neuroticism. Am Psychol.
2009;64(4):241‐256.
19. Smith DJ, Escott‐Price V, Davies G, et al. Genome‐wide analysis of
over 106 000 individuals identifies 9 neuroticism‐associated loci. Mol
Psychiatry. 2016;21:749.
20. Kotov R, Gamez W, Schmidt F, Watson D. Linking “big” personality
traits to anxiety, depressive, and substance use disorders: a meta‐
analysis. Psychol Bull. 2010;136(5):768‐821.
21. Cuijpers P, Smit F, Penninx BW, de Graaf R, ten Have M, Beekman AT.
Economic costs of neuroticism: a population‐based study. Arch Gen
Psychiatry. 2010;67(10):1086‐1093.
22. Hay JL, McCaul KD, Magnan RE. Does worry about breast cancer pre-
dict screening behaviors? A meta‐analysis of the prospective evidence.
Prev Med. 2006;42(6):401‐408.
23. Consedine NS, Magai C, KrivoshekovaYS, Ryzewicz L, Neugut AI. Fear,
anxiety, worry, and breast cancer screening behavior: a critical review.
Cancer Epidemiol Biomarkers Prev. 2004;13(4):501‐510.
24. Swanson JM, The UK. Biobank and selection bias. The Lancet.
2012;380(9837):110.
25. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: an open access
resource for identifying the causes of a wide range of complex diseases
of middle and old age. PLoS Med. 2015;12(3):e1001779.
26. Martin A, Rief W, Klaiberg A, Braehler E. Validity of the Brief Patient
Health Questionnaire Mood Scale (PHQ‐9) in the general population.
Gen Hosp Psychiatry. 2006;28(1):71‐77.
27. Smith DJ, Nicholl BI, Cullen B, et al. Prevalence and characteristics of
probable major depression and bipolar disorder within UK biobank:
cross‐sectional study of 172,751 participants. PLoS ONE. 2013;8(11):
e75362.
28. Eysenck HJ, Eysenck SBG. Manual of the Eysenck personality
questionnaire:(EPQ‐R adult): EdITS/Educational and Industrial Testing
Service; 1994.
29. Townsend P. Deprivation. J Soc Policy. 1987;16(2):125‐146.30. Jensen LF, Pedersen AF, Andersen B, Vedsted P. Self‐assessed health,
perceived stress and non‐participation in breast cancer screening: a
Danish cohort study. Prev Med. 2015;81:392‐398.
31. Jensen LF, Pedersen AF, Bech BH, Andersen B, Vedsted P. Psychiatric
morbidity and non‐participation in breast cancer screening. Breast.
2016;25:38‐44.
32. Jokela M, Batty GD, Hintsa T, Elovainio M, Hakulinen C, Kivimäki M. Is
personality associated with cancer incidence and mortality? An
individual‐participant meta‐analysis of 2156 incident cancer cases
among 42 843 men and women. Br J Cancer. 2014;110:1820.
33. Lemogne C, Consoli SM, Geoffroy‐Perez B, et al. Personality and the
risk of cancer: a 16‐year follow‐up study of the GAZEL cohort.
Psychosom Med. 2013;75(3):262‐271.
34. Schapiro IR, Ross‐Petersen L, Sælan H, Garde K, Olsen JH, Johansen C.
Extroversion and neuroticism and the associated risk of cancer: a
Danish cohort study. Am J Epidemiol. 2001;153(8):757‐763.
35. Pelosi AJ. Personality and fatal diseases: revisiting a scientific scandal.
J Health Psychol. 2019;24(4):421‐439.
36. Neeme M, Aavik A, Aavik T, Punab M. Personality and utilization of
prostate cancer testing: evidence for the influence of neuroticism
and conscientiousness. SAGE Open. 2015;5(3).
37. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of sociodemographic
and health‐related characteristics of UK Biobank participants with
those of the general population. Am J Epidemiol. 2017;186(9):
1026‐1034.
38. Batty GD, Gale C, Kivimaki M, Deary I, Bell S. Generalisability of results
from UK Biobank: comparison with a pooling of 18 cohort studies.
medRxiv. 2019:19004705.
39. Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical
precancer and reaching underscreened women by using HPV testing
on self samples: updated meta‐analyses. BMJ. 2018;363:k4823.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
How to cite this article: Niedzwiedz CL, Robb KA, Katikireddi
SV, Pell JP, Smith DJ. Depressive symptoms, neuroticism, and
participation in breast and cervical cancer screening: Cross‐
sectional and prospective evidence from UK Biobank. Psycho‐
Oncology. 2019;1–8. https://doi.org/10.1002/pon.5272
